
Francesco Sparano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3045697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials. Journal of the National Cancer Institute, 2022, 114, 471-474.	6.3	15
2	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 442-459.	0.4	7
3	Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. Frontiers in Oncology, 2022, 12, 826040.	2.8	5
4	Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Expert Review of Hematology, 2021, 14, 293-302.	2.2	5
5	Investigating Trends in the Quality of Reporting of Patient-Reported Outcomes in Oncology Over Time: Analysis of 631 Randomized Controlled Trials Published Between 2004 and 2019. Value in Health, 2021, 24, 1715-1719.	0.3	6
6	Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials. Clinical Practice and Epidemiology in Mental Health, 2021, 17, 307-314.	1.2	4
7	Investigating the impact of open label design on patientâ€reported outcome results in prostate cancer randomized controlled trials. Cancer Medicine, 2020, 9, 7363-7374.	2.8	19
8	Harnessing the patient voice in prostate cancer research: Systematic review on the use of patientâ€reported outcomes in randomized controlled trials to support clinical decisionâ€making. Cancer Medicine, 2020, 9, 4039-4058.	2.8	11
9	Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: AÂPooled Analysis of 229 Trials. Value in Health, 2020, 23, 666-673.	0.3	13
10	Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. BMC Urology, 2019, 19, 86.	1.4	10
11	Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?. Journal of Comparative Effectiveness Research, 2019, 8, 279-288.	1.4	4
12	Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review. BMJ Supportive and Palliative Care, 2019, 9, bmjspcare-2019-001902.	1.6	4
13	Does the quality of patient-reported outcomes (PROs) assessment in randomized controlled trials (RCTs) differ across cancer types and over time? A pooled analysis of 610 RCTs published between 2004 and 2018 Journal of Clinical Oncology, 2019, 37, e18218-e18218.	1.6	1
14	Inclusion of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) with elderly cancer patients: A systematic review Journal of Clinical Oncology, 2019, 37, e18217-e18217.	1.6	1
15	Patientâ€reported outcome assessment in acute leukemias: Moving beyond the barriers. Cancer, 2018, 124, 3066-3067.	4.1	1
16	Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review. Supportive Care in Cancer, 2018, 26, 2075-2090.	2.2	21
17	PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEW. Value in Health, 2018, 21, S76-S77.	0.3	0